Given that NRF2 activation occurs in a large subset (~93%) of pancreatic cancers, further optimization and formulation of this lead compound may provide a novel biomarker-guided therapeutic approach to treating pancreatic cancer. This evidence concerns the gene NFE2L2 and familial pancreatic carcinoma.